The downgrade by a major financial institution like JP Morgan, coupled with a drastic reduction in price target, is likely to negatively impact investor sentiment towards Metagenomi in the short term. This could lead to a decrease in stock price as market participants adjust their expectations based on the new analyst rating and price target.